Asia Pacific Long-Term Injectable Drug Delivery Market Size and Forecast (2021

Description

List of Tables

The Asia Pacific Long-Term Injectable Drug Delivery Market is projected to grow from US$ 1,287.1 Million in 2025 to US$ 3,053.2 Million by 2034. The market is expected to register a CAGR of 10.1% during the forecast period from 2026 to 2034.

Executive Summary and Asia Pacific Long-Term Injectable Drug Delivery Market Analysis:

The Asia Pacific Long-Term Injectable Drug Delivery Market, covering Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific, is expanding as healthcare systems respond to the increasing prevalence of chronic and lifestyle-related diseases. Conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders frequently require prolonged treatment and, in many cases, injectable therapies. Long-acting formulations are gaining attention because they can decrease administration frequency, support medication adherence, and improve treatment continuity.

Demographic changes are another important factor contributing to market expansion. The region has a rapidly increasing elderly population, creating greater demand for long-term disease management and biologic therapies that are commonly administered through injectable routes. At the same time, improvements in drug delivery technology are providing patients with more convenient treatment options. Prefilled syringes, autoinjectors, microneedle-based systems, and connected or smart injection devices are increasingly being developed to facilitate self-administration and support home-based treatment.

Pharmaceutical and biotechnology companies are increasing investments in innovative formulations, sterile manufacturing capacity, and advanced delivery platforms. Partnerships with regional device manufacturers, contract development organizations, and other specialized suppliers are also helping accelerate commercialization. Growing healthcare infrastructure, rising medical expenditure, and greater awareness of advanced injectable therapies among healthcare professionals and patients are further strengthening market prospects.

As healthcare providers increasingly emphasize patient convenience, adherence, and decentralized care, long-term injectable delivery technologies are expected to become an increasingly important component of chronic disease management throughout Asia Pacific.

Strategic Insights

Asia Pacific Long-Term Injectable Drug Delivery Market Segmentation Analysis:

By Formulation Packaging (Ready-to-Use), the Asia Pacific Long-Term Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment dominated the market in 2025.

By Therapeutic Application, the market is divided into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Others. The Diabetes segment accounted for the largest share in 2025.

By Route of Administration, the market is categorized into Subcutaneous, Intramuscular, Intravenous, and Others. The Subcutaneous segment led the market in 2025.

By Usability, the market comprises Disposable Injectors and Re-usable Injectors. Disposable Injectors represented the dominant segment in 2025.

By End User, the market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. Pharmaceutical and Biopharma Companies held the leading position in 2025.

Market Report Scope

Asia Pacific Long-Term Injectable Drug Delivery Market Outlook

The increasing demand for long-acting biologics and biosimilars in autoimmune disorders and oncology is creating significant opportunities for long-term injectable drug delivery technologies. Patients managing chronic and debilitating conditions often require prolonged treatment, making reduced dosing frequency an important factor in improving adherence and overall quality of life. Extended-release injectable formulations can minimize injection fatigue while maintaining therapeutic drug concentrations for longer periods.

Ustekinumab is an important example of a long-acting biologic, with subcutaneous administration at extended intervals following initial loading doses for conditions including moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. In oncology, pegfilgrastim provides prolonged granulocyte colony-stimulating factor activity and is generally administered as a single subcutaneous injection during each chemotherapy cycle to reduce the risk of febrile neutropenia in appropriate patients.

The growing availability of biosimilars is also influencing the long-term injectable landscape. Regulatory authorities have approved biosimilar versions of products such as pegfilgrastim and ustekinumab after evaluations demonstrating comparable quality, safety, and therapeutic performance. These alternatives can potentially improve treatment accessibility while providing healthcare systems with additional therapeutic choices.

Demand for these therapies is closely connected to the growing global burden of autoimmune diseases and cancer. As healthcare delivery increasingly shifts toward patient-centered treatment, long-acting formulations and biosimilars can help simplify treatment schedules and improve continuity of care. Consequently, ongoing innovation in injectable formulations, delivery devices, and biosimilar development is expected to create additional opportunities across the Asia Pacific market.

Asia Pacific Long-Term Injectable Drug Delivery Market Country Insights

By country, the Asia Pacific Long-Term Injectable Drug Delivery Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held the largest market share in 2025.

China represents a major market for long-term injectable drug delivery because of its large population, increasing chronic disease burden, aging demographics, and expanding healthcare capabilities. Diabetes and cancer are particularly significant contributors to demand for sustained drug delivery technologies. A 2025 national study estimated that approximately 233 million people in China were living with diabetes in 2023, while International Diabetes Federation estimates indicated around 148 million adults aged 20-79 had diabetes in 2024. Cancer also represents a substantial healthcare burden, with millions of new cases reported annually.

The high prevalence of diabetes is creating opportunities for long-acting insulin and GLP-1-based therapies, while oncology applications include extended-release and depot formulations used in treatment and supportive care. These technologies can reduce administration frequency and improve treatment consistency, particularly as urbanization and population aging increase demand for convenient chronic-care solutions.

China is also becoming increasingly active in the development of innovative injectable therapies. In January 2026, the National Medical Products Administration approved ecnoglutide injection, described as a long-acting cAMP-biased GLP-1 receptor agonist for adults with type 2 diabetes. Gan & Lee Pharmaceuticals has also advanced GZR4, an ultra-long-acting weekly insulin candidate, into clinical development.

In addition, approvals and development programs involving long-acting growth hormone and granulocyte colony-stimulating factor formulations demonstrate China's growing emphasis on sustained-release drug technologies. Combined with improvements in domestic pharmaceutical manufacturing and healthcare infrastructure, these developments are expected to support continued adoption of long-term injectable therapies.

Asia Pacific Long-Term Injectable Drug Delivery Market Company Profiles

Key companies operating in the Asia Pacific Long-Term Injectable Drug Delivery Market include Terumo Corp, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Schott AG, AptarGroup Inc, Becton Dickinson and Co, Owen Mumford Ltd, and SHL Medical.

These companies are pursuing strategies such as regional expansion, product development, technological innovation, strategic collaborations, manufacturing investments, and mergers and acquisitions. Through these initiatives, market participants are seeking to enhance injectable delivery technologies, improve patient usability, strengthen production capabilities, and expand their presence across the rapidly developing Asia Pacific market.

Product Code: TIPRE00044022

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Long-Term Injectable Drug Delivery Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Asia Pacific Long-Term Injectable Drug Delivery Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Long-Term Injectable Drug Delivery Market - Asia Pacific Analysis

5.1 Asia Pacific Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021 - 2034
5.2 Asia Pacific Long-Term Injectable Drug Delivery Market Revenue Forecast and Analysis

6. Asia Pacific Long-Term Injectable Drug Delivery Market Revenue Analysis - by Formulation Packaging (ready-to-use)

6.1 Asia Pacific Long-Term Injectable Drug Delivery Market Forecast and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
  - 6.1.1.1 Overview
  - 6.1.1.2 Ampoules: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Vials
  - 6.1.2.1 Overview
  - 6.1.2.2 Vials: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.3 Cartridges
  - 6.1.3.1 Overview
  - 6.1.3.2 Cartridges: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.4 Bottles
  - 6.1.4.1 Overview
  - 6.1.4.2 Bottles: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. Asia Pacific Long-Term Injectable Drug Delivery Market Revenue Analysis - by Therapeutic Application

7.1 Asia Pacific Long-Term Injectable Drug Delivery Market Forecast and Analysis by Therapeutic Application
- 7.1.1 Diabetes
  - 7.1.1.1 Overview
  - 7.1.1.2 Diabetes: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Oncology
  - 7.1.2.1 Overview
  - 7.1.2.2 Oncology: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
  - 7.1.3.1 Overview
  - 7.1.3.2 Auto-Immune Disorders: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Cardiovascular Diseases: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Infectious Diseases
  - 7.1.5.1 Overview
  - 7.1.5.2 Infectious Diseases: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.6 Pain Management
  - 7.1.6.1 Overview
  - 7.1.6.2 Pain Management: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.7 Others
  - 7.1.7.1 Overview
  - 7.1.7.2 Others: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. Asia Pacific Long-Term Injectable Drug Delivery Market Revenue Analysis - by Route Of Administration

8.1 Asia Pacific Long-Term Injectable Drug Delivery Market Forecast and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
  - 8.1.1.1 Overview
  - 8.1.1.2 Subcutaneous: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Intramuscular
  - 8.1.2.1 Overview
  - 8.1.2.2 Intramuscular: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Intravenous
  - 8.1.3.1 Overview
  - 8.1.3.2 Intravenous: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.4 Others
  - 8.1.4.1 Overview
  - 8.1.4.2 Others: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. Asia Pacific Long-Term Injectable Drug Delivery Market Revenue Analysis - by Usability

9.1 Asia Pacific Long-Term Injectable Drug Delivery Market Forecast and Analysis by Usability
- 9.1.1 Disposable Injectors
  - 9.1.1.1 Overview
  - 9.1.1.2 Disposable Injectors: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 9.1.2 Re-usable Injectors
  - 9.1.2.1 Overview
  - 9.1.2.2 Re-usable Injectors: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

10. Asia Pacific Long-Term Injectable Drug Delivery Market Revenue Analysis - by End User

10.1 Asia Pacific Long-Term Injectable Drug Delivery Market Forecast and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
  - 10.1.1.1 Overview
  - 10.1.1.2 Pharmaceutical and Biopharma Companies: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
  - 10.1.2.1 Overview
  - 10.1.2.2 CMOs and CDMOs: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

11. Asia Pacific Long-Term Injectable Drug Delivery Market - Country Analysis

11.1 Asia Pacific
- 11.1.1 Asia Pacific Long-Term Injectable Drug Delivery Market Forecast and Analysis - by Country
  - 11.1.1.1 China Market
    - 11.1.1.1.1 China: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.1.2 China: Asia Pacific Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.1.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.1.2.2 Therapeutic Application
      - 11.1.1.1.2.3 Route Of Administration
      - 11.1.1.1.2.4 Usability
      - 11.1.1.1.2.5 End User
  - 11.1.1.2 Japan Market
    - 11.1.1.2.1 Japan: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.2.2 Japan: Asia Pacific Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.2.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.2.2.2 Therapeutic Application
      - 11.1.1.2.2.3 Route Of Administration
      - 11.1.1.2.2.4 Usability
      - 11.1.1.2.2.5 End User
  - 11.1.1.3 India Market
    - 11.1.1.3.1 India: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.3.2 India: Asia Pacific Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.3.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.3.2.2 Therapeutic Application
      - 11.1.1.3.2.3 Route Of Administration
      - 11.1.1.3.2.4 Usability
      - 11.1.1.3.2.5 End User
  - 11.1.1.4 Australia Market
    - 11.1.1.4.1 Australia: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.4.2 Australia: Asia Pacific Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.4.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.4.2.2 Therapeutic Application
      - 11.1.1.4.2.3 Route Of Administration
      - 11.1.1.4.2.4 Usability
      - 11.1.1.4.2.5 End User
  - 11.1.1.5 South Korea Market
    - 11.1.1.5.1 South Korea: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.5.2 South Korea: Asia Pacific Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.5.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.5.2.2 Therapeutic Application
      - 11.1.1.5.2.3 Route Of Administration
      - 11.1.1.5.2.4 Usability
      - 11.1.1.5.2.5 End User
  - 11.1.1.6 Rest of Asia Pacific Market
    - 11.1.1.6.1 Rest of Asia Pacific: Asia Pacific Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.6.2 Rest of Asia Pacific: Asia Pacific Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.6.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.6.2.2 Therapeutic Application
      - 11.1.1.6.2.3 Route Of Administration
      - 11.1.1.6.2.4 Usability
      - 11.1.1.6.2.5 End User

12 Long-Term Injectable Drug Delivery Market Industry Landscape

13 - Key Company Profiles

13.1 Terumo Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Phillips-Medisize
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Gerresheimer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 West Pharmaceutical Services Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Ypsomed Holding AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Schott AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AptarGroup Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Becton Dickinson and Co
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SHL Medical
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 Glossary
14.2 Research Methodology and Approach
- 14.2.1 Secondary Research
- 14.2.2 Primary Research
- 14.2.3 Market Estimation Approach
  - 14.2.3.1 Supply Side Analysis
  - 14.2.3.2 Demand Side Analysis
- 14.2.4 Research Assumptions and Limitations
- 14.2.5 Currency Conversion
14.3 About The Insight Partners
14.4 Market Intelligence Cloud